Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis DOI Creative Commons
Tiantian Hua, Rui Fan, Fan Yang

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: May 24, 2024

Solid cancer patients, compared to their healthy counterparts, are at a greater risk of contracting and suffering from severe complications poorer prognosis after COVID-19 infections. They also have different immune responses doses vaccination, but limited evidence is available reveal the effectiveness help guide immunization programs for this subpopulation; MEDLINE, Embase, Web Science, Cochrane Library databases, clinicaltrials.gov were used search literature. The pooled seroconversion rate was calculated using random-effects model reported with 95% confidence interval (CI); review includes 66 studies containing serological vaccination in 13,050 solid patients 8550 controls. seropositive rates first dose controls 55.2% (95% CI 45.9%–64.5% N = 18) 90.2% 80.9%–96.6% 13), respectively. second 87.6% 84.1%–90.7% 50) 98.9% 97.6%-99.7% 35), third 91.4% 85.4%–95.9% 21) 99.8% 98.1%-100.0% 4), Subgroup analysis finds that study sample size, timing antibody testing, vaccine type influence on results; Seroconversion significantly lower malignancies, especially dose, then shrinking gradually following two vaccinations, indicating subsequent or booster should be considered subpopulation.

Language: Английский

Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis DOI Creative Commons
Tiantian Hua, Rui Fan, Fan Yang

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: May 24, 2024

Solid cancer patients, compared to their healthy counterparts, are at a greater risk of contracting and suffering from severe complications poorer prognosis after COVID-19 infections. They also have different immune responses doses vaccination, but limited evidence is available reveal the effectiveness help guide immunization programs for this subpopulation; MEDLINE, Embase, Web Science, Cochrane Library databases, clinicaltrials.gov were used search literature. The pooled seroconversion rate was calculated using random-effects model reported with 95% confidence interval (CI); review includes 66 studies containing serological vaccination in 13,050 solid patients 8550 controls. seropositive rates first dose controls 55.2% (95% CI 45.9%–64.5% N = 18) 90.2% 80.9%–96.6% 13), respectively. second 87.6% 84.1%–90.7% 50) 98.9% 97.6%-99.7% 35), third 91.4% 85.4%–95.9% 21) 99.8% 98.1%-100.0% 4), Subgroup analysis finds that study sample size, timing antibody testing, vaccine type influence on results; Seroconversion significantly lower malignancies, especially dose, then shrinking gradually following two vaccinations, indicating subsequent or booster should be considered subpopulation.

Language: Английский

Citations

4